Tumor endothelial cell autophagy is a key vascular-immune checkpoint in melanoma
Jelle Verhoeven1,2, Kathryn A Jacobs1,2, Francesca Rizzollo1,2
1Cell Death Research and Therapy Laboratory, Center for Cancer Biology, VIB, Leuven, Belgium.
Abstract:
Tumor endothelial cells (TECs) actively repress inflammatory responses and maintain an immune-excluded tumor phenotype. However, the molecular mechanisms that sustain TEC-mediated immunosuppression remain largely elusive. Here, we show that autophagy ablation in TECs boosts antitumor immunity by supporting infiltration and effector function of T-cells, thereby restricting melanoma growth. In melanoma-bearing mice, loss of TEC autophagy leads to the transcriptional expression of an immunostimulatory/inflammatory TEC phenotype driven by heightened NF-kB and STING signaling. In line, single-cell transcriptomic datasets from melanoma patients disclose an enriched InflammatoryHigh /AutophagyLow TEC phenotype in correlation with clinical responses to immunotherapy, and responders exhibit an increased presence of inflamed vessels interfacing with infiltrating CD8+ T-cells. Mechanistically, STING-dependent immunity in TECs is not critical for the immunomodulatory effects of autophagy ablation, since NF-kB-driven inflammation remains functional in STING/ATG5 double knockout TECs. Hence, our study identifies autophagy as a principal tumor vascular anti-inflammatory mechanism dampening melanoma antitumor immunity.
Related Concept Videos
Tumor Immunotherapy
The Tumor Microenvironment
Regulation of Angiogenesis and Blood Supply
mTOR Signaling and Cancer Progression
The mTOR pathway or the...


